Global 
Sverige 
USA Stille AB: Interim Report Q3 2022
Revenues increased by 17 percent to 59.6 MSEK (51.1). Operating profit increased by 32 percent to 7.2 MSEK (5.5). Positive currency effects of 2.7 MSEK affected the result after financial items.
Revenues for Surgical Instruments increased by six percent to 30.1 MSEK (28.4). Profitability was affected by an unfavorable product and geographic market mix. Surgical Table-revenues grew by 30 percent to 29.5 MSEK (22.7). Sales have been particularly strong in EMEA with a growth of 47 percent.
The challenging environment, primarily with disturbances in supply chains, has affected Stille during the quarter. This has however not affected sales. The challenges are expected to continue going forward.
”The long waiting lists for elective surgery remains and must be addressed regardless. Stille contributes with premium products enabling maximal efficiency. With market leading brands, and cost-control, Stille stands well-prepared for the future", concludes Hanna Ernestam Wilkman.
| MSEK | jul-sept 2022 |
jul-sept 2021 |
jan-sept 2022 |
jan-sept 2021 |
oct-sept 2021/22 |
jan-dec 2021 |
| Revenue | 59.6 | 51.1 | 184.5 | 127.5 | 244.1 | 187.1 |
| Gross Profit Margin, % | 45.1 | 45.0 | 45.1 | 44.2 | 45.5 | 44.6 |
| Operating Profit | 7.2 | 5.5 | 23.6 | 14.6 | 29.1 | 20.1 |
| Operating Profit, % | 12.1 | 10.7 | 12.8 | 11.4 | 12.1 | 10.7 |
| EBITDA | 9.4 | 7.4 | 30.4 | 19.3 | 38.0 | 26.8 |
| Net Income | 6.5 | 3.4 | 19.6 | 10.2 | 25.6 | 16.1 |
Torshälla, October 27th, 2022.
This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on October 27th, 2022, kl. 08.00 (CET).
